George Bickerstaff, III net worth and biography

George Bickerstaff, III Biography and Net Worth

Director of Innoviva

George W. Bickerstaff III has served as a member of our Board of Directors since December 2017 and as Chairman of the Board of Directors since December 2020. He is currently Chair of the Audit Committee and a member of our Compensation Committee. He currently serves as a Managing Director of M.M. Dillon & Co., LLC, an investment banking firm. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global leader in pharmaceuticals and consumer health, including Chief Financial Officer of Novartis Pharma AG. Prior to joining Novartis, Mr. Bickerstaff was the Chief Financial Officer of IMS Health, Division of Dun & Bradstreet. Mr. Bickerstaff currently serves on the board of directors of CareDx, Inc. and Cardax, Inc. Mr. Bickerstaff previously served on the board of directors of Axovant Sciences Ltd, Inovio Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. until it was acquired by Takeda Pharmaceutical Company Limited in February 2017. He holds degrees in engineering and business administration from Rutgers University and Executive Education credentials from Harvard Business School.

What is George Bickerstaff, III's net worth?: The estimated net worth of George Bickerstaff, III is at least $2.08 million as of May 21st, 2021. Mr. Bickerstaff, III owns 114,560 shares of Innoviva stock worth more than $2,082,701 as of March 30th. This net worth estimate does not reflect any other investments that Mr. Bickerstaff, III may own. Learn More about George Bickerstaff, III's net worth.
How do I contact George Bickerstaff, III?: The corporate mailing address for Mr. Bickerstaff, III and other Innoviva executives is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. Innoviva can also be reached via phone at (650) 238-9600 and via email at investor.relations@inva.com. Learn More on George Bickerstaff, III's contact information.
Has George Bickerstaff, III been buying or selling shares of Innoviva?: George Bickerstaff, III has not been actively trading shares of Innoviva during the past quarter. Most recently, on Monday, May 24th, George Bickerstaff bought 10,000 shares of Innoviva stock. The stock was acquired at an average cost of $13.46 per share, with a total value of $134,600.00. Following the completion of the transaction, the director now directly owns 114,560 shares of the company's stock, valued at $1,541,977.60. Learn More on George Bickerstaff, III's trading history.
Who are Innoviva's active insiders?: Innoviva's insider roster includes George Bickerstaff, III (Director), and Marianne Zhen (CAO). Learn More on Innoviva's active insiders.
Are insiders buying or selling shares of Innoviva?: During the last year, insiders at the biotechnology company sold shares 2 times. They sold a total of 1,347,921 shares worth more than $23,632,205.17. The most recent insider tranaction occured on March, 6th when Major Shareholder Alexander J Denner sold 1,196,746 shares worth more than $20,966,989.92. Insiders at Innoviva own 1.7% of the company. Learn More about insider trades at Innoviva.
Information on this page was last updated on 3/6/2025.

George Bickerstaff, III Insider Trading History at Innoviva

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/24/2021	Buy	10,000	$13.46	$134,600.00	114,560
5/21/2021	Buy	10,000	$12.97	$129,700.00	114,560
2/27/2019	Buy	15,000	$15.90	$238,500.00
2/21/2019	Buy	10,000	$14.90	$149,000.00	38,762

George Bickerstaff, III Buying and Selling Activity at Innoviva

Innoviva Company Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Today's Range

Now: $18.18

$17.84

$18.34

50 Day Range

MA: $17.99

$17.21

$18.98

2 Week Range

Now: $18.18

$14.33

$21.28

Volume

829,709 shs

Average Volume

616,706 shs

Market Capitalization

$1.14 billion

P/E Ratio

26.35

Dividend Yield

N/A

Beta

0.56